Micromet, Amgen sign BiTE antibodies pact
The agreement allows Amgen to develop and commercialize BiTE antibodies against two of the undisclosed targets which will be selected by Amgen. Amgen will be responsible to develop,
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.